• Altimmune posted results from a Phase 2b IMPACT trial analysis of pemvidutide in biopsy-confirmed F2–F3 MASH.
• AI-based qFibrosis digital pathology showed a significant reduction in continuous fibrosis score at week 24 versus placebo.
• Pooled pemvidutide doses produced a significantly higher share of patients with at least 1 qFibrosis stage regression at week 24.
• Trial enrolled 212 patients across placebo (86), 1.2 mg pemvidutide (41), 1.8 mg pemvidutide (85) arms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.